Trump Reveals $250 Weight Loss Medications in New ‘TrumpRx’ Agreement

Trump Announces Discounts for Weight Loss Drugs

President Donald Trump recently announced significant reductions in prices for GLP-1 weight loss medications during an Oval Office briefing. Collaborating with pharmaceutical companies Eli Lilly and Novo Nordisk, Trump revealed that Lilly’s Zepbound and Novo Nordisk’s Wegovy will soon be available at lower prices through a new direct-to-consumer platform called TrumpRx, expected to launch by year’s end.

Currently, Wegovy costs around $1,350 per month, but under this new agreement, it will be available for $250. Zepbound, which typically runs about $1,080 monthly, will be priced at $346. The aim is to ensure these GLP-1 medications, which are taken orally instead of through injections, will be less than $149 each month moving forward.

According to Trump, Americans pay vastly higher prices—520% more for Zepbound and an astonishing 1,400% more for Wegovy—when compared to patients in Europe.

Mehmet Oz, who oversees the Centers for Medicare and Medicaid Services, indicated that the TrumpRx website is planned to go live before the year wraps up. Trump expressed confidence about its success, noting, “It has to be successful. It has my name on it.”

Additionally, Eli Lilly has committed $27 billion, while Novo Nordisk will invest $10 billion into domestic drug manufacturing. Trump highlighted this initiative as a matter of national security, reflecting on the challenges faced during the COVID-19 pandemic, when the U.S. struggled to produce necessary medications domestically and had to rely on suppliers in China.

This new pricing strategy is a result of an executive order signed in May aimed at establishing “most-favored-nation” pricing for medications. The goal here is to secure the lowest possible drug prices globally, while alleviating the excessive costs Americans often face, despite contributing substantially to global research and development through NIH funding.

The executive order mandates the U.S. Trade Representative and the Department of Commerce to ensure fair contributions from foreign nations towards drug research and also instructs the Department of Health and Human Services to negotiate lower consumer prices in line with those found in European countries.

To encourage compliance from pharmaceutical companies, the administration hinted at implementing “a series of aggressive reforms,” which could include new CMS regulations and FTC enforcement, along with reevaluating drug export and import protocols. The companies have also promised to adhere to most-favored-nation pricing for any new medications they develop.